RxDoctor Payments DataLook up a doctor →

Nicholas Kolinsky

Allergy & Immunology · Knoxville, TNNPI 1033569439

Payments from drug & device makers

$472,397in general payments, 2019–2025

Across 1,202 payments — averaging $393.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$319K
  • Regeneron Healthcare Solutions, Inc.$36K
  • GSK$27K
  • CSL Behring$21K
  • Ionis Pharmaceuticals, Inc.$19K
  • Sanofi$9K
  • plus $42K from 40 others

What the payments were for

  • Consulting fees$20,0984%
  • Speaking & faculty fees$391,96583%
  • Travel & lodging$22,6905%
  • Food & beverage$37,1438%
  • Education$5020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$472,397 in reported general payments places this provider in the 95th percentile of 79 allergy & immunology providers in Tennessee.

See all allergy & immunology providers in Tennessee

Medicare billing

Part B allowed, 2024
$301,406
Medicare patients
887
Services billed
18,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter293$231,482
XolairOmalizumab47$175,497
TezspireTezepelumab-Ekko36$149,881
FasenraBenralizumab19$108,412
Dupixent SyringeDupilumab18$77,946
RyaltrisOlopatadine Hcl/Mometasone56$17,524
Advair HfaFluticasone Propion/Salmeterol36$11,934
Breo ElliptaFluticasone/Vilanterol28$11,117
SymbicortBudesonide/Formoterol Fumarate40$10,824
Epinephrine40$8,126
Spiriva RespimatTiotropium Bromide14$7,092
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,848
Arnuity ElliptaFluticasone Furoate24$6,171
Cromolyn Sodium13$5,013
Azelastine Hcl110$3,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Fasenra, Symbicort, Breztri Aerosphere$319,430$275,964106 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$26,795$248,770345 claims
Genentech, Inc.Xolair$30$175,49747 claims
Hikma Pharmaceuticals USARyaltris, Epinephrine$6,251$25,65196 claims
Boehringer IngelheimSpiriva Respimat$29$7,09214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 allergy & immunology providers in Tennessee.

Other allergy & immunology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →